LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. AU="Lange, Mona V"
  2. AU="Bruner, Brenda G"
  3. AU="Michael Craigen"
  4. AU="Lambard, G."
  5. AU="Dempsey, Connor P"
  6. AU=Li Youxian
  7. AU="Bhosale, Chanakya R"

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.

    Ebenig, Aileen / Lange, Mona V / Mühlebach, Michael D

    NPJ vaccines

    2022  Volume 7, Issue 1, Page(s) 119

    Abstract: Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA ... ...

    Abstract Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to generate infectious negative-strand RNA viruses on the basis of viral genomes encoded on plasmid DNA in the 1990s, paved the way to generate recombinant, vaccine strain-derived MeVs. These live-attenuated vaccine constructs can encode and express additional foreign antigens during transient virus replication following immunization. Effective humoral and cellular immune responses are induced not only against the MeV vector, but also against the foreign antigen cargo in immunized individuals, which can protect against the associated pathogen. This review aims to present an overview of the versatility of this vaccine vector as platform technology to target various diseases, as well as current research and developmental stages, with one vaccine candidate ready to enter phase III clinical trials to gain marketing authorization, MV-CHIK.
    Language English
    Publishing date 2022-10-15
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2059-0105
    ISSN (online) 2059-0105
    DOI 10.1038/s41541-022-00543-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article: Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds

    Schmitz, Katharina S. / Lange, Mona V. / Gommers, Lennert / Handrejk, Kim / Porter, Danielle P. / Alabi, Christopher A. / Moscona, Anne / Porotto, Matteo / de Vries, Rory D. / de Swart, Rik L.

    Viruses. 2022 May 29, v. 14, no. 6

    2022  

    Abstract: Measles virus (MV) is a highly contagious respiratory virus responsible for outbreaks associated with significant morbidity and mortality among children and young adults. Although safe and effective measles vaccines are available, the COVID-19 pandemic ... ...

    Abstract Measles virus (MV) is a highly contagious respiratory virus responsible for outbreaks associated with significant morbidity and mortality among children and young adults. Although safe and effective measles vaccines are available, the COVID-19 pandemic has resulted in vaccination coverage gaps that may lead to the resurgence of measles when restrictions are lifted. This puts individuals who cannot be vaccinated, such as young infants and immunocompromised individuals, at risk. Therapeutic interventions are complicated by the long incubation time of measles, resulting in a narrow treatment window. At present, the only available WHO-advised option is treatment with intravenous immunoglobulins, although this is not approved as standard of care. Antivirals against measles may contribute to intervention strategies to limit the impact of future outbreaks. Here, we review previously described antivirals and antiviral assays, evaluate the antiviral efficacy of a number of compounds to inhibit MV dissemination in vitro, and discuss potential application in specific target populations. We conclude that broadly reactive antivirals could strengthen existing intervention strategies to limit the impact of measles outbreaks.
    Keywords COVID-19 infection ; Measles morbillivirus ; antiviral agents ; immunoglobulins ; intravenous injection ; measles ; morbidity ; mortality ; risk ; vaccination ; viruses
    Language English
    Dates of publication 2022-0529
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article
    ZDB-ID 2516098-9
    ISSN 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14061186
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds.

    Schmitz, Katharina S / Lange, Mona V / Gommers, Lennert / Handrejk, Kim / Porter, Danielle P / Alabi, Christopher A / Moscona, Anne / Porotto, Matteo / de Vries, Rory D / de Swart, Rik L

    Viruses

    2022  Volume 14, Issue 6

    Abstract: Measles virus (MV) is a highly contagious respiratory virus responsible for outbreaks associated with significant morbidity and mortality among children and young adults. Although safe and effective measles vaccines are available, the COVID-19 pandemic ... ...

    Abstract Measles virus (MV) is a highly contagious respiratory virus responsible for outbreaks associated with significant morbidity and mortality among children and young adults. Although safe and effective measles vaccines are available, the COVID-19 pandemic has resulted in vaccination coverage gaps that may lead to the resurgence of measles when restrictions are lifted. This puts individuals who cannot be vaccinated, such as young infants and immunocompromised individuals, at risk. Therapeutic interventions are complicated by the long incubation time of measles, resulting in a narrow treatment window. At present, the only available WHO-advised option is treatment with intravenous immunoglobulins, although this is not approved as standard of care. Antivirals against measles may contribute to intervention strategies to limit the impact of future outbreaks. Here, we review previously described antivirals and antiviral assays, evaluate the antiviral efficacy of a number of compounds to inhibit MV dissemination in vitro, and discuss potential application in specific target populations. We conclude that broadly reactive antivirals could strengthen existing intervention strategies to limit the impact of measles outbreaks.
    MeSH term(s) Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; COVID-19 ; Child ; Humans ; Measles ; Measles Vaccine ; Measles virus ; Pandemics ; Vaccination
    Chemical Substances Antiviral Agents ; Measles Vaccine
    Language English
    Publishing date 2022-05-29
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14061186
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters.

    Nouailles, Geraldine / Adler, Julia M / Pennitz, Peter / Peidli, Stefan / Teixeira Alves, Luiz Gustavo / Baumgardt, Morris / Bushe, Judith / Voss, Anne / Langenhagen, Alina / Langner, Christine / Martin Vidal, Ricardo / Pott, Fabian / Kazmierski, Julia / Ebenig, Aileen / Lange, Mona V / Mühlebach, Michael D / Goekeri, Cengiz / Simmons, Szandor / Xing, Na /
    Abdelgawad, Azza / Herwig, Susanne / Cichon, Günter / Niemeyer, Daniela / Drosten, Christian / Goffinet, Christine / Landthaler, Markus / Blüthgen, Nils / Wu, Haibo / Witzenrath, Martin / Gruber, Achim D / Praktiknjo, Samantha D / Osterrieder, Nikolaus / Wyler, Emanuel / Kunec, Dusan / Trimpert, Jakob

    Nature microbiology

    2023  Volume 8, Issue 5, Page(s) 860–874

    Abstract: Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune ...

    Abstract Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.
    MeSH term(s) Animals ; Cricetinae ; Humans ; Vaccines, Attenuated ; SARS-CoV-2 ; COVID-19/prevention & control ; COVID-19 Vaccines ; BNT162 Vaccine ; Pandemics ; Mesocricetus
    Chemical Substances sCPD9 COVID-19 vaccine ; Vaccines, Attenuated ; COVID-19 Vaccines ; BNT162 Vaccine
    Language English
    Publishing date 2023-04-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2058-5276
    ISSN (online) 2058-5276
    DOI 10.1038/s41564-023-01352-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top